Imran Ali is the Senior Manager of the pan-Canadian Pharmaceutical Alliance Office and has been in the role since September 2015. From 2012 to 2015, Imran held the position of Senior Manager with the Agreements & Negotiations Unit in the Ontario Ministry of Health and Long-Term Care’s Negotiations Branch. In this role, Imran provided leadership and direction for planning, priority setting and negotiation of accountability agreements with individual providers and health care organizations to optimize the Ministry’s investment in the health care system valued at over $11 billion annually. Imran provided support for the negotiations process with the Ontario Medical Association (OMA). Prior to this, Imran supported the negotiations of the 2012 Physician Services Agreement with the OMA and lead the coordination of subsequent implementation activities related to the agreement. He also served as the Ministry Co-Chair for the Systems Management Committee, which is responsible for bilateral monitoring and analysis of physician services in Ontario with the OMA. Imran began his career with the Ministry in 2006 with the Primary Health Care Branch where he managed physician services contracts valued in excess of $50 million annually in the Specialized Models Unit. Imran graduated with a Masters in Public Health specializing in Health Policy and Management from the University of Alberta's School of Public Health in 2005.
Deborah Maskens, is a kidney cancer patient and patient advocate. Her current roles include Vice-Chair of the International Kidney Cancer Coalition (IKCC). Along with another patient, she Co-Founded Kidney Cancer Canada and played an active role for 10 years. During this time she focused on advocacy, health technology assessment, and patient navigation.
Deb is currently a Patient Advocate on the NCI Renal Task Force. She is a also a Patient Panel member of the HTAi Patient and Citizen Involvement group (HTAi.org) and Co-Lead of the CanCertainty Coalition campaign of 35 cancer organizations advocating for health policy change across Canada (CanCertainty.ca).
In 2016, Deb was awarded the Canadian Governor General’s Meritorious Service Medal, Canada’s highest award for her dedication and professionalism in patient advocacy and volunteer service.
Deb is a frequent speaker at national and international cancer meetings where she provides the patient voice perspective, along with sound advocacy knowledge and experience.
Eric Tse is the General Manager for Shire in Canada. As the head of one of the fastest growing biotechnology companies in the country, he is responsible for pursuing and accelerating the Canadian expansion of Shire with a special focus on the areas of rare diseases and other high-need conditions.
Since joining Shire in October 2013, Eric has led the Canadian team through a series of successful transformations, including two integrations and the consolidation the company’s commercial operations under a single corporate entity, both strengthening and expanding the Shire footprint in Canada.
Under his leadership, Shire also implemented a comprehensive, best-in-class patient assistance program for Canadians living with rare diseases, in addition to achieving leadership positions in the areas of ADHD and ulcerative colitis in Canada.
Today, following the recent combination with Baxalta, Eric is at the helm of an expanded, Shire team, with increase capabilities and a renewed focus to enable people with rare diseases and other highly specialized conditions to lead better lives.
Eric is a Board Member of BIOTECanada. He holds an MBA from the University of Toronto’s Rotman School of Business and a BA from Queen’s University, Kingston, Ontario.
John Anacleto is the Director of Payer Relations with McKesson Canada and is responsible for various private and public payer engagements. He has over eleven years of experience working in the pharmaceutical industry serving multiple pharmaceutical manufacturers and government institutions.
Prior to his current role, John was with TELUS Health Analytics, managing a team that provided consultation on the Canadian reimbursement landscape and insurance market trends. Client engagements included providing strategic input on how to engage the private and public insurance industries in Canada and data to support market access strategies. His knowledge on the Canadian reimbursement landscape spanned various therapeutic areas, including but not limited to: oncology, arthritis, diabetes, pain and vaccines.
As a consultant, John’s economics background was invaluable in constructing Budget Impact Assessment models, patient assistance financial models, analyzing patient access for private and public insurance, analyzing claims data to determine drug and patient costs, and calculating patient’s ability-to-pay for medication.
He has also written several articles on access to insurance coverage in Canada, plan design and longitudinal trends in private plans, and plan sponsor health benefit trends.
Nadia Turchetta is the Executive Director of Biosimilars at Sandoz Canada. Nadia joined Sandoz in January 2016 after spending almost 13 years at Novartis, where she worked in different roles including sales, market research, marketing and sales management.
Nadia’s academic background includes an Honors Bachelor of Business Administration at the Richard Ivey School of Business, University of Western Ontario.
Nadia is also an active member of Biosimilars Canada and a co-chair of the Canadian Biosimilars Forum.
For over a decade Sandoz, a Novartis division, has been the pioneer and global leader in biosimilars. This year marks ten years since Sandoz launched the world’s first biosimilar, Omnitrope®, in the EU, giving rise to the era of affordable biologics that have helped to treat millions of patients and liberate billions of dollars in healthcare costs. Sandoz continues to invest in research and development into these life changing medicines.
John-Paul is Managing Director of Roubaix Strategies Inc. He brings more than 20 years of experience working in the health and pharmaceutical sectors. His experience and knowledge in market access and negotiation strategy covers an extensive scope of therapeutic and business areas, across both the public and private drug markets in Canada.
Roubaix Strategies Inc. delivers an essential suite of services that will make a difference in gaining the best possible market access:
Private Market Insights – know the market
Health and Specialty Care Analytics – know the data
e-Advisory Boards – know the thinking
Pharma Negotiation Training – know how!
Originally from Vancouver, Alan Birch currently resides in Toronto. He is an administrator at the Oncology Drug Access Navigators of Ontario (ODANO). Within ODANO, Alan facilitates education for fellow members, does advocacy for patients as well as maintaining the ODANO website at www.odano.ca. In addition to ODANO duties, Alan is a drug access navigator at North York General Hospital.
Alan is a Pharmacy Technician by background and has been working in oncology for the past 5 years. He is a member of the Ontario College of Pharmacists and the Ontario Pharmacists Association.
Kaitlyn Proulx is PDCI Market Access’ Managing Director and is responsible for managing the firm and leading the staff of twenty senior consultants and supporting staff. By offering full-service strategic pricing and market access consulting services, Kaitlyn and her team assist clients across all stages of pricing and reimbursement activities.
Kaitlyn provides ongoing advice with respect to pricing and reimbursement strategy to help ensure timely listing on drug plan formularies. She maintains a strong working relationship with drug plan managers across Canada facilitating access to payers, decision makers and the latest information on drug plan policies and regulations.
In his current role within Pharmaceutical Services Division (PSD), Eric leads the Drug Intelligence and Optimization branch.
The branch is responsible for determining which drugs are included in the BC PharmaCare formulary through the national Common Drug Review (CDR-CADTH) process, the pan-Canadian Pharmaceutical Alliance (pCPA) negotiation process, and the provincial Drug Benefit Council (DBC) review process. The branch also is responsible for adjudicating drug funding requests through Special Authority, supporting the optimal and appropriate use of drugs in BC (e.g. supporting prescribing guidelines and academic detailing), and leading other specialty programs and initiatives.
Prior to joining PSD in 2007, Eric worked with the Vancouver Coastal Health Authority as Regional Coordinator, Medication Use Management. Eric has also worked as a financial research analyst for the biotech and healthcare sector (TD Securities), as a clinical pharmacist (Vancouver General Hospital), a Drug Use Evaluation pharmacist (University of Alberta Hospital), and a pharmacy lecturer (University of Technology, Jamaica).
As the National Practice Leader, Drug Benefits Solutions in Great-West Life’s Toronto Group Sales Office, Barbara A. Martinez supports sales offices across Canada on prescription drug management initiatives. She plays a key role in supporting advisors and their clients, including designing and managing drug benefit plans with Great-West Life Drug Solutions programs.
Barbara joined Great-West Life in 2012 after 10 years at Mercer, where she led the Canadian drug benefits consulting team. She’s a regular speaker at industry forums and a frequent commentator on employer drug programs. Her past experience also includes 13 years in the pharmaceutical industry, where she worked in sales and marketing as well as government and professional affairs.
Michèle Chadwick is the lead on the Regulatory Review of Drugs and Devices Team within the Health Products and Food Branch at Health Canada.
Michèle has worked within the Federal Health Portfolio for 17 years both Health Canada and Public Health Agency and Health Canada in various policy and regulatory capacities, predominantly in the realm of therapeutic products.
Prior to coming to the federal government she worked in the pharmaceutical Industry for 10 years.
Chris Goguen is the Strategic Pharmaceutical Partnerships Lead within the Drug Management Solutions team at Medavie Blue Cross. The focus of his role is strengthening Medavie’s business relationships with the pharmaceutical industry, to design services and agreements that result in savings for plan sponsors, and to mobilize innovative partnerships that advance improved health outcomes.
Chris joined Medavie Blue Cross in 2015, with 25 years of experience as a senior leader within the research-based pharmaceutical industry in Canada. With the majority of his career focussed on External Affairs, including strategy and relationship development with governments, private payers & other health stakeholders across Canada, Chris has developed expertise in drug pricing, access, negotiation and patient health management strategies. He has played a lead role in development and implementation of numerous disease [drug] management partnership programs, impacting both public and private health system outcomes.
Lorna has successfully held senior leadership roles in a number of national charities over the past twenty years, and has a diverse background in fundraising, communications, strategic planning and mission development. Lorna spent the past eleven years working with The Leukemia & Lymphoma Society of Canada, most recently as Senior National Director, Mission Programs & Corporate Communications. She has a stellar reputation and is frequently asked to present on the emerging trends and critical issues in the Canadian lymphoma landscape.
Mrs. Karine Alloul currently holds the position of Senior Manager, Health Economics and Health Outcomes at Sanofi. Over the past decade, she has covered a variety of therapeutic areas including cardiovascular disease, central nervous system diseases and more predominantly oncology. Karine holds a Bachelor in Pharmacy and a Master’s degree in Pharmaceutical Sciences focusing on drug development from the University of Montreal. Karine has over 20 years' experience working in the pharmaceutical industry, where she held various positions in clinical research, market research, sales training and market access. She has led innovative outcomes research projects measuring the impact of health management interventions conducted in collaboration with private payers and employers. Her other fields of expertise include assessing quality of life in cancer patients, assessment of treatment patterns, and validation of outcomes in real world settings in partnership with payers.
Neil Corner leads the Health Access and Outcomes division for the Canada business unit of QuintilesIMS . In this role he is focused on supporting federal and provincial government, academics and the pharmaceutical industry in understanding and delivering health outcomes data, economic modelling, payer research and access strategies.
Neil’s team utilizes data from Electronic Medical Records, prescription data, claims data, patient reported outcomes and administrative data sources to support the appropriate evidence creation for a pharmaceutical or medical device intervention. He has lead the development of strategic partnerships, with groups such as the Hub Research Centre at St Michael’s hospital to bring together cutting edge methodologies and the most robust EMR data available for research.
Neil has more than 25 years of pharmaceutical industry experience in the UK, US, EMEA and Canada.
Jeremy Slobodan is the Director, Drug Utilization, Information & Stewardship for Alberta Health Services and is based out of Red Deer. His position oversees the AHS drug formulary, drug information and antimicrobial stewardship for Pharmacy Services.
In part, his role includes improving patient care through optimized drug use and working with practitioners to ensure new drugs introduced onto the AHS formulary provide improvements to the health care system.
Jeremy is the Chair of the National Hospital Formulary Collaborative, a member of the Alberta Health Expert Committee on Drug Evaluation & Therapeutics and a past president of the Alberta Pharmacists Association."
Christopher Trevors, MS, CGC graduated with a B.Sc. (Honours) in Biology from Queen’s University and a master’s degree in Human Genetics (Genetic Counseling) from Sarah Lawrence College in Bronxville, New York. He worked at the Westchester Medical Center in Hawthorne, New York before starting at The Hospital for Sick Children (SickKids) in Toronto as a genetic counsellor. During his nine years at SickKids he was involved in clinical care before taking on a role as a clinical educator and evaluator in the areas of genetics, ethics and molecular/genomic technologies. Christopher worked as Canadian General Manager of Centogene AG, a German molecular diagnostics company for 3 years before transitioning to help build a genetic diagnostics division at LifeLabs in Toronto as Director of Genetics and Genomics. Christopher is currently the National Director of Genetic Health Solutions at Dynacare and continues to lecture in the University of Toronto Genetic Counselling MSc program, the Medical Laboratory Technology Program at The Michener Institute and the George Brown Nursing Program.
A career public servant, Tanya Potashnik possesses a breadth of knowledge in the area of pharmaceutical policy, market dynamics and pricing in Canada and internationally. Prior to this role, Tanya served as manager and senior economist at the Board in charge of, among other things, the National Prescription Drug Utilization Information System (NPDUIS) initiative. Tanya has also held various policy and management positions in the Federal Government and the BC Ministry of Health. Tanya received her Bachelors of Arts from the University of Winnipeg in Economics and Business and received her Masters of Arts from the University of Victoria in economics. Since January 2013, Tanya has served as Director of Policy and Economic Analysis Branch at the Patented Medicine Prices Review Board where she is responsible for leading the development of strategic policy advice, economic analysis and management of stakeholder relations for the Board.
Heather is currently the Director of Healthcare and Innovation at Roche Canada, responsible for Personalized Healthcare, Foundation Medicine, Biologic Strategy and Strategic Account Management. She currently sits as the Chair of the Operating Committee for the Canadian Pharmaceutical Distribution Network (CPDN) and has worked on various other industry association committees. Heather has over a decade of experience working in the Pharmaceutical industry, with a strong focus in oncology. She has worked on both the clinical development side and on the commercial side in various roles such as Global Project Management, Account Management, Corporate Development, Operations Management and Biologic Strategy. The cross-functional nature of her roles has provided her with knowledge in strategic corporate ventures, laboratory diagnostics, patient programs, biosimilars, medical affairs, market access and government relations. Heather holds an HBSc. in Biology from the University of Western Ontario and a Project Management Professional (P.M.P.) designation.
As Director, Strategic Partnerships at the Institute for Clinical Evaluative Sciences (ICES), Alison Paparica leads work to explore and evaluate new initiatives that have the potential to become ICES core business. This includes ICES work with the private sector, which began as a pilot in 2015 and is now a regular service offering, and new initiatives such as the Pan-Canadian Real-world Health Data Network - PRHDN. In addition, she serves as the main coordinating point of contact with key ICES partners including Health Quality Ontario, Cancer Care Ontario and the Ontario SPOR SUPPORT Unit. Alison is also Assistant Professor (Status) at the Institute for Health Policy, Management and Evaluation at the University of Toronto.
Prior to joining ICES, Alison was the Director of the Planning, Research & Analysis Branch at the Ontario Ministry of Health & Long-Term Care, responsible for up to $60 million annual investment in health services and population health research, and extensive knowledge translation and exchange activities to ensure that research findings were understood and used in health system policy development and planning.
From 1994-2001, Alison worked in international pharmaceutical R&D at Eli Lilly, Astra Pharma, and Genpharm Inc. She has her PhD in organic chemistry from the University of Western Ontario, Project Management Professional (PMP) certification since 2001, and was a fellow in Canadian Foundation for Healthcare Improvement's EXTRA program.
Brad Millson is a Principal within the Health Access and Outcomes consulting group at QuintilesIMS.
Brad leads projects to deliver market access strategy and real-world evidence-based solutions for the pharmaceutical industry and its stakeholders. He joined the company in 2013, bringing his global expertise in pharmaceutical brand management, strong medical science training and strategic problem solving to the team.
Brad has over 15 years of experience in the Life Sciences industry globally, across government and private sectors. In Canada, he is recognized for his expertise in health outcomes, market access and policy strategy.
Prior to joining QuintilesIMS (formerly IMS Brogan), he led the investment attraction function for Life Sciences at the Department of Foreign Affairs and International Trade, assisting global life science companies entering the Canadian market. Brad spent several years in the US at a leading biotech strategy consulting firm, developing solutions in new product launch, marketing, sales, and business development for the global headquarters of top pharmaceutical and biotech companies, spanning key therapeutic areas such as Oncology and Immunology
Brad is a Dean’s List graduate of the MBS program (integrated MSc Biotech + MBA ) at Keck Graduate Institute in Claremont, California, and holds a BSc in Physiology from McGill University. Brad speaks English and French, and is conversational in Mandarin Chinese.
Pamela Fralick is an experienced leader who has been fostering positive change in Canada’s health sector for decades. Throughout her career, Ms. Fralick has distinguished herself in a variety of senior roles. A convener and innovator, Ms. Fralick is one of Canada’s leading, compassionate voices in the health sector. As the President of Innovative Medicines Canada, Ms. Fralick leads the industry association for Canada’s innovative pharmaceutical companies, working with its members and communities to ensure Canadians have access to the medicines they need, when they need them. Prior to joining Innovative Medicines Canada, Ms. Fralick was President and CEO of the Canadian Cancer Society, Canada’s largest health charity, where she oversaw a three-year process of intense transformation, resulting in historic changes to the operational and governance structures of the organization. Ms. Fralick previously served as president and CEO of the Canadian Healthcare Association (CHA) and as CEO of the Canadian Physiotherapy Association. At both Associations, Ms. Fralick led organizational initiatives designed to enhance sustainability and improve outcomes for the associations, their members and stakeholders. Ms. Fralick has also held senior positions with the Canadian Centre on Substance Abuse and Health Canada’s Alcohol and Other Drugs Unit. True to her commitment to the health and well-being of Canadians, Ms. Fralick has served on numerous prestigious boards and collaboratives across Canada. She was Chair of the Health Action Lobby (HEAL) and Co-chair the Canadian Coalition for Public Health in the 21st Century (CCPH21). She has been active in many organizations as a senior volunteer, including the Centre for Addiction and Mental Health, the University of Ottawa Institute of Mental Health Research, Triathlon Canada and the International Triathlon Union. She is currently on the board of Outward Bound Canada (Chair) and the Canada Dance Festival (Past Chair). Ms. Fralick has a BA in French and psychology and an MA in developmental psychology from Carleton University, as well as a Master of Public Administration (MPA) from Queen’s University. She also holds an ICD.D designation. She is trilingual – in English, French and German – and is an accomplished artist and athlete.